Amedisys, Inc. (NASDAQ:AMED) Given Average Recommendation of "Hold" by Brokerages

Amedisys, Inc. (NASDAQ:AMED - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $100.67.

A number of equities research analysts have weighed in on the company. William Blair lowered Amedisys from an "outperform" rating to a "market perform" rating in a research note on Monday, July 1st. Deutsche Bank Aktiengesellschaft lowered Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price objective for the company. in a research note on Monday, July 29th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $101.00 price objective on shares of Amedisys in a research note on Thursday, July 25th.

Amedisys Trading Down 0.7 %

Amedisys stock traded down $0.66 during midday trading on Tuesday, reaching $95.85. The stock had a trading volume of 525,584 shares, compared to its average volume of 331,899. Amedisys has a twelve month low of $89.55 and a twelve month high of $98.95. The stock has a market capitalization of $3.13 billion, a PE ratio of -149.77, a price-to-earnings-growth ratio of 1.90 and a beta of 0.78. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.16 and a current ratio of 1.16. The stock's 50-day simple moving average is $97.59 and its 200 day simple moving average is $95.00.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings data on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.22 by $0.10. The firm had revenue of $591.19 million for the quarter, compared to analyst estimates of $579.34 million. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. Analysts expect that Amedisys will post 4.66 EPS for the current year.

Institutional Trading of Amedisys

Institutional investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise bought a new stake in Amedisys during the first quarter valued at $60,000. Innealta Capital LLC bought a new position in shares of Amedisys during the second quarter worth about $64,000. Covestor Ltd grew its position in shares of Amedisys by 134.2% during the first quarter. Covestor Ltd now owns 780 shares of the health services provider's stock worth $72,000 after acquiring an additional 447 shares during the last quarter. Signaturefd LLC grew its position in shares of Amedisys by 88.2% during the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider's stock worth $104,000 after acquiring an additional 530 shares during the last quarter. Finally, GAM Holding AG bought a new position in shares of Amedisys during the second quarter worth about $275,000. Institutional investors own 94.36% of the company's stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.